Inari Medical Inc
NASDAQ:NARI
Inari Medical Inc
EPS (Diluted)
Inari Medical Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inari Medical Inc
NASDAQ:NARI
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
EPS (Diluted)
$6
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
0%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
22%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$7
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$7
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
18%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$6
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
|
Inari Medical Inc
Glance View
Inari Medical Inc., nestled in the heart of Irvine, California, embarked on a mission to revolutionize the treatment for venous diseases with a sense of urgency and ingenuity. Founded in 2011, this medical device company has become a beacon of innovation in the healthcare sector, relentlessly focused on addressing the unmet needs in the treatment of venous thromboembolism (VTE) conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These life-threatening conditions impact millions globally, presenting a critical challenge that Inari aims to tackle head-on. Their pioneering spirit is showcased in their flagship devices—the FlowTriever and ClotTriever—designed to remove large clots with less risk compared to traditional, invasive surgical methods. By providing minimally invasive mechanical thrombectomy devices, Inari Medical has streamlined treatments to improve patient outcomes, ultimately reducing the burden on healthcare systems. Revenue streams at Inari are intrinsically tied to their innovative products, which are integral in modern therapeutic strategies for clot removal. The commercial success of FlowTriever and ClotTriever is driven by their effectiveness and safety profile, appealing to hospitals and medical professionals looking for advanced solutions to treat VTE. Inari's business model thrives on the sales and adoption of these devices, supported by robust clinical evidence that underpins their efficacy. With a blend of aggressive research and development, education programs for physicians, and a strategic global market expansion, Inari Medical is poised to continue growing in the med-tech sector. Their commitment to addressing large medical needs with cutting-edge solutions not only defines their financial blueprint but also underscores their dedication to transforming patient care across the globe.
See Also
What is Inari Medical Inc's EPS (Diluted)?
EPS (Diluted)
-0
USD
Based on the financial report for Dec 31, 2023, Inari Medical Inc's EPS (Diluted) amounts to -0 USD.
What is Inari Medical Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
33%
Over the last year, the EPS (Diluted) growth was 95%.
You don't have any saved screeners yet